Compare NSRX & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSRX | PIII |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | Israel | United States |
| Employees | 7 | 320 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 32.0M |
| IPO Year | N/A | N/A |
| Metric | NSRX | PIII |
|---|---|---|
| Price | $3.16 | $9.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $19.67 | $9.00 |
| AVG Volume (30 Days) | 11.0K | ★ 21.6K |
| Earning Date | 03-25-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.67 |
| Revenue Next Year | N/A | $2.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $1.52 |
| 52 Week High | $9.99 | $16.89 |
| Indicator | NSRX | PIII |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 45.86 |
| Support Level | $2.83 | $9.47 |
| Resistance Level | $3.60 | $11.57 |
| Average True Range (ATR) | 0.16 | 0.79 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 28.87 | 35.41 |
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.